By Karen Roman
Biopharmaceutical company Medera Inc. said it finished patient dosing in the trial of SRD-001, its gene therapy candidate for heart failure with reduced ejection fraction.
Additionally, Medera and Keen Vision Acquisition Corporation (Nasdaq: KVAC) announced they had entered into a definitive merger agreement on September 2024.
“We are very excited and encouraged by these results, which indicate that our various new designs such as optimized dosages seem to be making differences,” said Ronald Li, Ph.D., Medera’s co-founder and CEO.
Healthcare Edge
Editor@Executives-edge.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。